Restrictive cardiomyopathy has long been one of the most stubborn puzzles in heart medicine. The heart muscle in these patients becomes stiff, resisting the filling of the ventricles even when the pumping chambers themselves may still contract reasonably well. Patients often progress relentlessly toward heart failure, yet the condition is so rare and so variable from one person to the next that clinicians have struggled to classify it, let alone treat it.
A new study from a Chinese referral center now offers a genetic window into this enigmatic disorder, and its findings suggest that restrictive physiology may be far more genetically loaded than previously appreciated. Researchers at Zhongshan Hospital of Fudan University enrolled 568 patients with cardiomyopathy between 2019 and 2021, including 389 with hypertrophic cardiomyopathy, 172 with dilated cardiomyopathy, and just 7 with primary restrictive cardiomyopathy. Using prespecified echocardiographic criteria, they searched across the entire cohort for patients whose hearts showed the hallmarks of restrictive filling: elevated filling pressures, a characteristic transmitral inflow pattern, and enlargement of both atria.
Patients with significant valve disease, pericardial disease, or constrictive physiology were excluded. Thirty-three patients met the definition, and crucially, the investigators did not simply relabel advanced hypertrophic or dilated cases as primary restrictive disease. Instead, they kept those patients in hybrid categories, dubbed HRCM and HDRCM, to preserve the original diagnostic framework while capturing the restrictive physiology that cut across it.
The headline result is striking: 24 of the 33 patients, or 72.7 percent, carried a pathogenic or likely pathogenic variant identified through whole-exome sequencing. For a condition often described as an orphan disease with unclear origins, that diagnostic yield is remarkably high. Variants were classified according to the American College of Medical Genetics and Genomics criteria, with reads aligned to the GRCh37 reference genome and rare coding and splice-site variants prioritized by population frequency, predicted consequence, phenotype consistency, and segregation evidence where family data were available.
MYBPC3 variants appeared predominantly in patients classified as having hypertrophic cardiomyopathy with restrictive physiology, with one additional carrier in the dilated-restrictive group who also carried a variant in DES, the desmin gene. Variants in TTR, the transthyretin gene central to cardiac amyloidosis, and in LAMP2, linked to Danon disease, turned up in patients whose imaging showed overlapping hypertrophic-restrictive or dilated-restrictive features. The picture that emerges is one of converging molecular pathways: several distinct genetic insults can funnel the heart toward the same stiff, restrictive endpoint.
Genotype also left fingerprints on the echocardiogram. MYBPC3 carriers showed greater anteroseptal and maximum left ventricular wall thickness and more frequent septal hypertrophy than carriers of other variants. A detailed segmental analysis, dividing the left ventricular wall into 16 segments on short-axis views, revealed that MYBPC3 carriers had hypertrophy in every single anteroseptal and inferoseptal segment, both at the base and mid-cavity level, compared with roughly half of non-MYBPC3 carriers.
Composite septal scores differed significantly between the groups, with nominal p-values of 0.008 to 0.012. Hypertrophy in the HRCM group was distributed relatively uniformly throughout the left ventricle, while the dilated-restrictive group showed a similar pattern with a strong predominance of interventricular septal involvement, seen in 83.33 percent of those patients. One of the more unexpected observations involved the aorta.
Genotype-positive patients had a smaller aortic sinus dimension than genotype-negative patients, averaging 30.79 millimeters versus 34.22 millimeters, a nominal p-value of 0.026. The authors are careful to frame this as exploratory: the comparison was not adjusted for multiple testing, the cohort was small, and aortic size can reflect body dimensions, loading conditions, age, or broader remodeling rather than any direct genetic mechanism. They explicitly caution that aortic sinus diameter should not be used on its own to guide genetic testing or risk stratification, and that multivariable analysis in a much larger cohort would be needed to establish an independent association.
Other imaging parameters told a more consistent story across the restrictive subgroup. Left ventricular ejection fraction averaged 47.18 percent, and 29 of the 33 patients showed both left and right ventricular systolic dysfunction. The average E/e' ratio, a measure of filling pressure, was 19.4, well above the diagnostic threshold of 14 used to define the phenotype.
Right ventricular hypertrophy was present in more than half the cohort and was more prominent in the hybrid HRCM and HDRCM groups than in primary restrictive cardiomyopathy, hinting that the restrictive physiology superimposed on hypertrophic or dilated disease drives a biventricular remodeling pattern distinct from either classic entity. The clinical outlook in this cohort was sobering. Estimated five-year survival was 54.5 percent, and survival did not differ significantly between carriers and non-carriers of reportable variants.
Multiple-organ failure was the most common recorded cause of death, followed by sudden cardiac death. The authors stress that these adverse outcomes are descriptive, drawn from a small number of events with limited follow-up, and require confirmation in larger longitudinal studies before any gene-specific prognostic claims can be made. What the study does support, the investigators argue, is a lower threshold for genetic evaluation when restrictive physiology appears on an echocardiogram, particularly when hypertrophic features, storage or infiltrative patterns, conduction disease, skeletal-muscle involvement, or family history coexist.
Combining whole-exome sequencing with systematic segmental phenotyping, they suggest, may sharpen the classification of ambiguous or mixed cardiomyopathy presentations and identify subgroups who could benefit from targeted therapies. The limitations deserve honest weight. The single-center referral design likely enriched the cohort for severe, diagnostically complex cases, and the participants' ethnicity, tertiary-care setting, and referral pathways may limit generalizability to community populations and other ancestries.
Whole-exome sequencing itself can miss deep intronic variants, structural variants, repeat expansions, and mitochondrial variants, so the true genetic yield could be even higher, or the spectrum of implicated genes broader, than what was captured. With only 33 restrictive-phenotype patients and small genotype subgroups, the many correlated imaging comparisons were hypothesis-generating at best.
Subject of Research: Genetic basis of restrictive physiology across hypertrophic, dilated, and primary restrictive cardiomyopathy
Article Title: Genetic Insights Into Cardiomyopathy With Restrictive Phenotype: Implications for Diagnosis and Personalized Care
Article References: Zhou, N., Sun, Y., Wei, X., Liang, W., Meng, F., Ge, Z., Sun, M., Cui, X., Zhang, S., Pan, C., Ge, J., & Shu, X. (2026). Genetic Insights Into Cardiomyopathy With Restrictive Phenotype: Implications for Diagnosis and Personalized Care. Molecular Genetics & Genomic Medicine, 14(11), Article e70323. https://doi.org/10.1002/mgg3.70323
Image Credits: AI Generated
DOI: 10.1002/mgg3.70323
Keywords: restrictive cardiomyopathy, MYBPC3, TTR, LAMP2, whole-exome sequencing, echocardiography, genotype-phenotype, hypertrophic cardiomyopathy, dilated cardiomyopathy, cardiac amyloidosis, genetic testing, heart failure
News Source: Juliet Wilcox. (October 26, 2026). Genes Behind a Rare Heart-Filling Disorder Point Toward Personalized Care. Scienmag.
